DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
compose your message
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle cell patients, families and doctors face a ‘fight for everything’
Francesca Valentine is gearing up for a fight with her insurance company over Endari, the new FDA-approved drug, which will likely be on the market in January. Endari is a highly refined version of a nutritional supplement called L-Glutamine, which has been shown to relax the stiff, sickle-shaped red blood cells of people with the disease. It’s the first of a number of new drugs in the pipeline and will cost about $3,300 per month for the average adult.
But many insurers plan to restrict how the drug covered. Several, including the Valentines’ Blue Cross Blue Shield’s Federal Employee Program, will cover Endari only if patients have “failed first” at other treatments, including blood transfusions and hydroxyurea (the only other drug available to treat sickle cell), even though in studies Endari appeared to be of benefit when given in conjunction with other treatments.
Community CenterSickle Cell Disease in the Emergency Department: Confronting Barriers to Care“You’re too pretty to have a disease...
education & researchSelf‐Management Recommendations for Sickle Cell Disease: A Content Analysis of WebsitesThis paper reports on the findings of a ...
education & researchAnxiety, Depression, Pain Intensity and Interference in Adult Patients with Sickle Cell DiseaseIntroduction: Previous sickle cell dise...
Community CenterExplorations Into the Microbiome of Individuals Living With Sickle Cell DiseaseWe know there are several different gene...
news & events7th Annual Leadership Summit and General Assembly of Patients, Caregivers & CBOsThe Sickle Cell Community Consortium (SC...
Community CenterChronically FearlessChronically Fearless blog welcomes all w...
news & eventsPhase 3 Trial of Rivipansel in Treating SCD Pain Crisis Fails to Meet Goals, Pfizer AnnouncesThe Phase 3 RESET trial testing the effe...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.